What is Akido Labs?
Akido Labs is at the forefront of revolutionizing the healthcare system by integrating artificial intelligence with empathy. The company's core mission is to deliver exceptional healthcare to all individuals through a reimagined model. Its proprietary technology is designed to transform the clinical experience, empowering both healthcare providers and patients. By unlocking new capabilities, Akido Labs is establishing an entirely new paradigm for healthcare delivery, focusing on efficiency, accessibility, and patient-centric care.
How much funding has Akido Labs raised?
Akido Labs has raised a total of $85.3M across 3 funding rounds:
Debt
$350K
Series A
$25M
Series B
$60M
Debt (2020): $350K with participation from PPP
Series A (2021): $25M led by Necessary Ventures
Series B (2025): $60M supported by Y Combinator, Oak HC/FT, Snr Investments, GrECo International, and Future Communities Capital
Key Investors in Akido Labs
Necessary Ventures
Necessary Ventures is a venture capital firm that invests in a wide range of sectors, technologies, and business models, focusing on pre-seed to pre-IPO stages. They lead investments of $1-2M and provide resources to help founders attract talent, raise non-dilutive capital, and enhance growth through media networks.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Oak HC/FT
Founded in 2014, Oak HC/FT is the premier venture growth-equity fund investing in Healthcare Information & Services ("HC") and Financial Services Technology ("FT"). With $3.3 billion in assets under management, we are focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to our extensive network of industry leaders.
What's next for Akido Labs?
With substantial enterprise-level backing and a recent strategic investment, Akido Labs is poised for accelerated growth. The company is expected to leverage this capital infusion to expand its technological capabilities, enhance its AI-driven platform, and broaden its market reach. Future developments will likely focus on deepening the integration of AI into clinical workflows, improving patient outcomes, and solidifying its position as a leader in empathetic, AI-powered healthcare. This financing round is a clear indicator of investor confidence in Akido Labs' vision to create a more accessible and effective healthcare ecosystem.
See full Akido Labs company page
